Last update 08 May 2025

MHS-552

Overview

Basic Info

Drug Type
Biological products
Synonyms
Target-
Action-
Mechanism-
Therapeutic Areas
Immune System DiseasesEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Diabetes Mellitus, Type 1Systemic Lupus Erythematosus
Originator Organization
Novartis AGNovartis AG
Active Organization-
Inactive Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with MHS-552
NCT05272059
/ WithdrawnPhase 1
A Randomized, Investigator and Participant Blinded, Placebo Controlled, Multiple Ascending Dose, Two Part Design Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of MHS552 in Adults With Type 1 Diabetes Mellitus (T1DM)
NCT05203419
/ TerminatedPhase 1
A Two-part, Randomized, Investigator- and Participant- Blinded, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MHS552 in Adult Participants With Systemic Lupus Erythematosus (SLE)
NL-OMON49201
/ CompletedNot Applicable
A first-in-human, randomized, subject-blinded, placebocontrolled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of MHS552 in healthy volunteers - A FIH study to investigate the safety, tolerability and PK of MHS552
100 Clinical Results associated with MHS-552
Login to view more data
100 Translational Medicine associated with MHS-552
Login to view more data
100 Patents (Medical) associated with MHS-552
Login to view more data
100 Deals associated with MHS-552
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1Phase 1-
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
01 Sep 2023
Systemic Lupus ErythematosusPhase 1
Germany
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
15 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free